The Integrated Forecasting and Analysis Tool   Login Now

Æterna Zentaris

EvaluatePharma® delivers unique insight into the past and future performance of companies in the pharmaceutical and biotechnology sector, in a user-friendly, online subscription service. A small selected sample of reports and related news headlines for Æterna Zentaris are available below. Free sample reports are also available for other Companies. To find out how you can access more detailed information on Æterna Zentaris, or on any other Company covered by EvaluatePharma® Contact Us today.

PIPELINE ANALYSIS - Sales Forecasts available to EvaluatePharma Subscribers

Rank Product Therapeutic Category Therapeutic Subcategory Pharmacological Class Phase (Current) Æterna Zentaris - Cetrorelix Genito-Urinary Female sex hormones LHRH antagonist Phase III   - Teverelix LA Oncology & Immunomodulators Hormone therapies LHRH antagonist Phase II   - AEZS-130 (EP-1572) Endocrine Growth hormones Growth hormone secretagogue Phase III

FINANCIAL DATA ($US mln) - Forecasts available to EvaluatePharma Subscribers

Æterna Zentaris   2005 2006  Valuation Measures   Based on Latest Share Prices      Valuing the Equity        Market Capitalisation 71 71        PE Ratio (diluted) - Normalised (x) (3.9) 9.6        Valuing the Enterprise        Enterprise Value 31 31        Free Cash Flow (Pre-Dividends) 16 7        FCF Yield (%) 51.1% 22.9%    Forecast Financials   Income Statement      Total Revenues 47 41      Cost of Goods Sold (9) (12)      S,G & A (15) (17)      R&D (27) (29)      Other Income/ Expense - Net (6) (8)      Associate/ Equity Affiliate Income - 2      EBIT - Normalised (10) (22)      Net Interest & Financial Items (6) 0      Pre-tax Profits - Normalised (15) (22)      Income Before Taxes (15) (22)      Tax 0 29      Tax Rate (%) 3.2% 133.4%      Discontinued Items 27 26      Net Income - Reported 11 33      Net Income - Normalised (16) 7     Per Share Data      EPS - Diluted 0.23 0.64      EPS - Basic 0.23 0.64      EPS - Normalised (diluted) (0.35) 0.14      EPS - Normalised (basic) (0.35) 0.14      Avg. Shares Outstanding - Diluted 46.1 52.5      Avg. Shares Outstanding - Basic 46.1 52.1      DPS 0.00 0.00

NEWS - Selected Product News Headlines (as of 11 June 2008)

Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology   (Keryx Biopharmaceuticals)   03-Jun-2008 Æterna Zentaris Announces First Patient Dosing for Safety Trial of Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia   (Æterna Zentaris)   14-May-2008 Æterna Zentaris: Article on Phase 2 Trial with Cetrorelix in BPH to be Published in European Urology Journal   (Æterna Zentaris)   13-May-2008 Æterna Zentaris’ Partner, Spectrum, Provides Update on Ozarelix in Benign Prostatic Hyperplasia   (Æterna Zentaris)   22-Apr-2008 Spectrum Pharmaceuticals Provides an Update on Ozarelix in BPH   (Spectrum Pharmaceuticals)   22-Apr-2008 Æterna Zentaris Completes Patient Recruitment for First Phase 3 Efficacy Trial with Cetrorelix in Benign Prostatic Hyperplasia   (Æterna Zentaris)   15-Apr-2008 Ardana Announces Preliminary Phase II Repeat Dose Results for Teverelix LA in Prostate Cancer   (Ardana)   09-Apr-2008 Æterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia   (Æterna Zentaris)   26-Mar-2008 Æterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers   (Æterna Zentaris)   12-Feb-2008 Ardana Announces Outcome of Pre-IND Meeting With FDA on Teverelix LA for the Treatment of Endometriosis   (Ardana)   09-Jan-2008 Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology   (Keryx Biopharmaceuticals)   10-Dec-2007 Ardana Announces Positive Preliminary Results in a Further Phase II Study of Teverelix LA in Benign Prostatic Hyperplasia   (Ardana)   21-Nov-2007 Early Results of Phase 2 Trial of Perifosine (KRX-0401) for the Treatment of Recurrent Malignant Gliomas Presented at the 12th Annual Scientific Meeting of Society for Neuro-Oncology   (Keryx Biopharmaceuticals)   19-Nov-2007 Æterna Zentaris Announces Completion of Patient Enrollment for Multi-Center Phase 2 Trial with Perifosine in Combination with Radiotherapy for Non-Small Cell Lung Cancer   (Æterna Zentaris)   14-Nov-2007 Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma   (Keryx Biopharmaceuticals)   05-Nov-2007 Æterna Zentaris to Further Develop Three Follow-up Multi targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment   (Æterna Zentaris)   25-Oct-2007 Æterna Zentaris Announces Outcome of Management’s Strategic Review   (Æterna Zentaris)   02-Oct-2007 Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale d'Urologie   (Spectrum Pharmaceuticals)   05-Sep-2007 Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstrom's Macroglobulinemia   (Keryx Biopharmaceuticals)   29-Jun-2007

IN-DEPTH COMPETITIVE INTELLIGENCE AVAILABLE ON

Product Generic Name Æterna Zentaris AEZS-108 (AN-152) -   AEZS-112 (ZEN-012) -   AEZS-112 follow-up compound 1 -   AEZS-112 follow-up compound 2 -   AEZS-112 follow-up compound 3 -   AEZS-130 (EP-1572) -   AN-207 -   AN-215 -   AN-238 -   Arthrovas -   Cetrorelix cetrorelix   Cetrotide cetrorelix   D-81050 -   D-82318 -   Disorazol E -   Erk/ PI3K Inhibitors -   Ghrelin Antagonists -   Impavido miltefosine   JMR-132 (GHRH Antagonist) -   Kinesin Inhibitors -   KRX-0401 perifosine   Lobaplatin lobaplatin   Neoretna -   Neovastat -   Ozarelix ozarelix   Psovascar -   RC-3095 -   Teverelix LA teverelix   Tumour Vaccine -   ZEN-014 -   ZEN-019 -   ZEN-027 erucylphosphocholine

EvaluatePharma® provides historic and forecast sales from 1986 to 2012 for worldwide and US Rx (prescription drugs) and OTC drugs. EvaluatePharma® analysts continuously update company models from SEC filings, annual reports, investor/analyst presentations, company press releases, FDA and USPTO. Consensus forecasts for marketed and emerging products are built-up using recent research reports from top equity analysts. Analyse pharma and biotech products by market status or development phase (e.g., preclinical, phase I, phase II, phase III, filed, approved, withdrawn, disposed etc), therapeutic category, product sourcing strategy, patent expiry and patent life remaining, originator, technology, indication, pharmacological class, deal dates, deal types and partners, launch dates, FDA approval data and new molecular entity (NME) age - plus many more data items and analytics unique to EvaluatePharma®. Aggregations of these measures at a high-level means that companies may be ranked against each other on items such as: market capitalization, patent risk, R&D spend, freshness index, sales strategy (inlicensed vs organic sales), sales by therapy area or technology and various other concentration measures. These aggregations make EvaluatePharma® ideal for competitive benchmarking, ranking and Peer Group analysis. Note: When a merger or acquisition is agreed, a virtual merged Company will be added to the list of available Company reports. Any information presented for a virtual merged company is for illustrative purposes, only.

Source: EvaluatePharma ®

Generated at 13:52:45 (GMT) on 11-Jun-2008

© 2008 EvaluatePharma Ltd